open access

Vol 14, No 4 (2018)
Other materials agreed with the Editors
Published online: 2019-02-12
Get Citation

Maciej Kawecki1
DOI: 10.5603/OCP.2018.0029
·
Oncol Clin Pract 2018;14(4):237-240.


Affiliations

  1. Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Institute of Oncology, Warsaw

open access

Vol 14, No 4 (2018)
CURRENT LITERATURE REVIEW
Published online: 2019-02-12

Abstract

Not available

Abstract

Not available
Get Citation
About this article
Title

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 4 (2018)

Article type

Other materials agreed with the Editors

Pages

237-240

Published online

2019-02-12

DOI

10.5603/OCP.2018.0029

Bibliographic record

Oncol Clin Pract 2018;14(4):237-240.

Authors

Maciej Kawecki

References (6)
  1. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20): 2017–2023.
  2. Raskob GE, van Es N, Verhamme P, et al. Hokusai VTE Cancer Investigators. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018; 378(7): 615–624.
  3. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345(23): 1655–1659.
  4. Mickisch GH, Garin A, van Poppel H, et al. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358(9286): 966–970.
  5. Méjean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. N Engl J Med. 2018; 379(5): 417–427.
  6. Conroy T, Hammel P, Hebbar M, et al. Unicancer GI PRODIGE 24/CCTG PA.6 trial: A multicenter international randomized phase III trial of adjuvant mFOLFIRINOX versus gemcitabine (gem) in patients with resected pancreatic ductal adenocarcinomas. Journal of Clinical Oncology. 2018; 36(18_suppl): LBA4001–LBA4001.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl